Description: Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Evotec's mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. Evotec has built a comprehensive suite of fully integrated, next generation technology platforms which it believes will transform the way new drugs are discovered. By leveraging the advanced capabilities of Evotec's integrated platforms, Evotec is able to provide solutions to its partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes.
Home Page: www.evotec.com
EVO Technical Analysis
Essener Bogen 7
Hamburg,
22419
Germany
Phone:
49 40 560 81 0
Officers
| Name | Title |
|---|---|
| Dr. Werner Lanthaler M.B.A., MBA, MPA, Ph.D. | Chairman of Management Board & CEO |
| Mr. Enno Spillner | CFO & Member of Management Board |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board |
| Dr. Craig Johnstone | COO & Member of Management Board |
| Dr. Matthias Evers | Chief Bus. Officer & Member of Management Board |
| Ms. Anja Bosler | Principal Accounting Officer and Sr. VP of Group Accounting |
| Mr. Volker Braun | Sr. VP and Global Head of Investor Relations & ESG |
| Dr. Christian Dargel | EVP Global Head of Legal & Compliance |
| Gabriele Hansen | Sr. VP & Head of Global Corp. Communications & Marketing |
| Ms. Monika Conradt | Global Head of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 89.2857 |
|---|---|
| Trailing PE: | 430 |
| Price-to-Book MRQ: | 2.2976 |
| Price-to-Sales TTM: | 4.1528 |
| IPO Date: | 2009-12-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 4715 |